CClinicalTrials.gg
RecruitingNCT06533397Updated Apr 24, 2026

The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation

An interventional study of Sinus floor elevation (SFE) and preoperative cone beam computed tomography (CBCT) in Alveolar Bone Loss and Edentulism Nos, sponsored by Semmelweis University. Recruiting at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Semmelweis University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Pneumatization of the maxillary sinus may lead to insufficient bone volume for dental implant placement in the edentulous posterior maxilla. Sinus floor elevation (SFE) surgery with the lateral window technique is a safe and predictable surgical intervention to restore bone height in the maxillary premolar and molar areas. According to the literature, several bone graft materials may be successfully applied for SFE surgery. There is a lack of evidence regarding the application of biphasic calcium sulfate (BCS) for SFE. The healing period following staged SFE is 2-9 months.

The aim of this study is:

  • to evaluate the success of SFE surgery using BCS as graft material,
  • to compare the microarchitecture of the augmented bone depending on the healing period,
  • to evaluate the success of dental implants placed in the augmented bone and that of the prostheses delivered on the dental implants.
02

Conditions studied

  • Alveolar Bone Loss
  • Edentulism Nos

Browse trials for

Keywords

  • bone graft material
  • biphasic calcium sulfate
  • sinus floor elevation
  • sinus lift
  • maxillary sinus augmentation
  • microcomputed tomography
  • cone beam computed tomography
  • histology
  • histomorphometry
  • dental implant
03

In context

Alveolar Bone Loss

297 studies on the registry are indexed under Alveolar Bone Loss; 76 are open to participants now.

This study's planned enrollment of 40 is above the median of 25 across 254 interventional studies indexed under Alveolar Bone Loss.

Browse Alveolar Bone Loss studies →

Lead sponsor

Semmelweis University is the lead sponsor of 136 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients over the age of 18 years,
  • Patients who need dental implant-borne prostheses,
  • Patients with insufficient bone height in the posterior maxilla due to sinus pneumatization.

Exclusion criteria

Exclusion criteria:

.• Patients who had major systemic diseases as classified by the American Society of Anesthesiologists (ASA grades III-IV),

  • psychiatric contraindications,
  • patients on medication interfering with bone metabolism, including steroid therapy and antiresorptive medication,
  • radiation to the head or neck region within the previous five years,
  • localized periapical disease, odontogenic and nonodontogenic cysts, and maxillary sinusitis,
  • evidence of uncontrolled periodontal disease,
  • Alcohol Use Disorder defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5),
  • recreational drug abuse,
  • heavy smoking (>10 cigarettes/day),
  • diseases of the oral mucosa, including blisters and ulcers, i.e.: red and white lesions, pigmented lesions, benign tumors of the oral cavity, and oral cancer. Leukoplakia, Erythroplakia, Precancerous lesions, Oral squamous cell carcinoma and malign tumors of the soft and hard tissues, Oral candidiasis, Oral lichen planus, Psoriasis, Pemphigus, and Pemphigoid.
  • pregnancy or nursing,
  • poor oral hygiene
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    3-month healing period

    Staged SFE is performed; following a 3-month-long healing period, bone core biopsy samples are harvested from the augmented bone, and dental implants are placed.

    Procedure: Sinus floor elevation (SFE) · Diagnostic Test: preoperative cone beam computed tomography (CBCT) · Diagnostic Test: postoperative CBCT · Diagnostic Test: bone core biopsy · Procedure: dental implant placement · Procedure: fixed dental prosthesis (FDP) fabrication · Device: bone grafting

  • Experimental
    6-month healing period

    Staged SFE is performed; following a 6-month-long healing period, bone core biopsy samples are harvested from the augmented bone, and dental implants are placed.

    Procedure: Sinus floor elevation (SFE) · Diagnostic Test: preoperative cone beam computed tomography (CBCT) · Diagnostic Test: postoperative CBCT · Diagnostic Test: bone core biopsy · Procedure: dental implant placement · Procedure: fixed dental prosthesis (FDP) fabrication · Device: bone grafting

Interventions

  • ProcedureSinus floor elevation (SFE)

    Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.

    Also known as: sinus lift surgery, maxillary sinus augmentation

  • Diagnostic testpreoperative cone beam computed tomography (CBCT)

    A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.

  • Diagnostic testpostoperative CBCT

    A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.

  • Diagnostic testbone core biopsy

    At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.

  • Proceduredental implant placement

    Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.

  • Procedurefixed dental prosthesis (FDP) fabrication

    3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.

  • Devicebone grafting

    A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.

06

What researchers measure

Primary outcomes

  1. Success of the SFE

    The SFE surgery is successful if no inflammatory complications occur in the 3- or 6-month-long healing period and the bone volume is sufficient for dental implant placement.

    Time frame: 3 or 6 months

  2. Success of the dental implants

    According to The International Congress of Oral Implantologists (ICOI) Pisa Consensus Conference. Success (optimum health) 1. No pain or tenderness upon function 2. 0 mobility 3. less than 2 mm radiographic bone loss from initial surgery 4. No exudates in the patient's history II. Satisfactory survival 1. No pain on function 2. 0 mobility 3. 2-4 mm radiographic bone loss 4. No exudates in the patient's history III. Compromised survival 1. May have sensitivity on function 2. No mobility 3. Radiographic bone loss of more than 4 mm (less than1/2 of the length of the implant body) 4. Probing depth more than 7 mm 5. May have exudates in the patient's history IV. Failure (clinical or absolute failure) Any of the following: 1. Pain on function 2. Mobility 3. Radiographic bone loss of more than 1/2 length of the implant 4. Uncontrolled exudate 5. Implant no longer in mouth

    Time frame: 5 years

  3. Success of the implant borne prostheses

    Prostheses with four or fewer complications (screw loosening, decementation, chipping) that could be treated chairside.

    Time frame: 5 years

Secondary outcomes

  1. Hisomorphometry: Percent of residual bone graft particles

    The percentage of residual bone graft particle-area measured on the representative sections prepared from the bone core biopsy samples. Unit: percent (%)

    Time frame: 3-6 months

  2. Hisomorphometry: Percent of newly formed bone

    The percentage of newly formed bone-area measured on the representative sections prepared from the bone core biopsy samples. Unit: percent (%)

    Time frame: 3-6 months

  3. Hisomorphometry: Percent of bone marrow

    The percentage of bone marrow-area measured on the representative sections prepared from the bone core biopsy samples. Unit: percent (%)

    Time frame: 3-6 months

  4. Value of the percent bone volume (BV/TV) calculated from the microCT reconstructions of the bone core biopsy samples.

    Relative volume of calcified tissue in the selected volume. Unit: none

    Time frame: 3-6 months

  5. Value of the bone surface to volume ratio (BS/TV), calculated from the microCT reconstructions of the bone core biopsy samples.

    Ratio of the segmented bone surface to the total volume in the region of interest. Unit: 1/mm

    Time frame: 3-6 months

  6. Value of the trabecular thickness (Tb.Th.), calculated from the microCT reconstructions of the bone core biopsy samples.

    Mean thickness of the trabeculae, assessed using direct 3D methods. Unit: mm

    Time frame: 3-6 months

  7. Value of the trabecular separation (Tb.Sp.), calculated from the microCT reconstructions of the bone core biopsy samples.

    Mean distance between the trabeculae, assessed using direct 3D methods. Unit: mm

    Time frame: 3-6 months

  8. Value of the trabecular bone pattern factor (Tb.Pf), calculated from the microCT reconstructions of the bone core biopsy samples.

    Indicator of the relation between convex and concave elements in the trabecular bone structure. Tb.Pf \<0 when the trabecular bone is honeycomb-like and increases as the trabecular bone acquires a rod-like structure. Unit: none

    Time frame: 3-6 months

  9. Value of the structure model index (SMI), calculated from the microCT reconstructions of the bone core biopsy samples.

    The estimator of the plate- versus rod-like characteristic of the trabecular bone structure, 0 for perfect plates, 3 for perfect rods, and 4 for perfect spheres. Unit: none

    Time frame: 3-6 months

  10. Value of the Total porosity (Po(tot)), calculated from the microCT reconstructions of the bone core biopsy samples.

    Percent porosity is the volume of pores as a percent of the total volume of interest (VOI). Unit: percent (%)

    Time frame: 3-6 months

  11. Value of the Connectivity (Conn.), calculated from the microCT reconstructions of the bone core biopsy samples.

    One useful and fast algorithm for calculating the Euler connectivity in 3D is the "Conneulor". It measures what might be called "redundant connectivity", the degree to which parts of the object are multiply connected. It is a measure of how many connections in a structure can be severed before the structure falls into two separate pieces. Unit: none.

    Time frame: 3-6 months

07

Study locations

1 of 1 sites recruiting
  • Semmelweis University Department of Public Dental Health
    Budapest, Budapest 1088, Hungary
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533397
Lead sponsor
Semmelweis University
Responsible party
Marton Kivovics (associate professor, Semmelweis University) — Principal investigator
First posted
Aug 1, 2024
Start date
Aug 24, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2031 (estimated)
Last update
Apr 24, 2026

Study contacts

Márton Kivovics, DMD,MSD,PHD
Contact
kivovics.marton@semmelweis.hu
003614591500 ext. 60732
Dorottya Pénzes, DMD,MSD,PHD
Contact
dorottya.penzes@semmelweis.hu
003614591500 ext. 60759
Márton Kivovics, DMD,MSD,PHD
principal investigator · Department of Public Dental Health, Semmelweis University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion